Hospital
Fostoria Hospital Association
Fostoria Hospital Association was paid $7.48M by Medicaid between Jan 2018 and Dec 2024, across 150 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoFOSTORIA HOSPITAL ASSOCIATION
FOSTORIA, OH 44830
FOSTORIA, OH 44830
33aNPI1275533226assigned 07/29/2005
33bProvider typeCritical Access Hospital
28Total paid$7.48M
24GClaims140,594
24DCodes billed150
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Ohio
Rank by total paid#11 of 26
Median peer was paid$5.33M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,610 | $381K | |
| 2019 | 6,513 | $374K | |
| 2020 | 5,403 | $345K | |
| 2021 | 6,828 | $449K | |
| 2022 | 7,686 | $573K | |
| 2023 | 60,085 | $2.88M | |
| 2024incomplete | 48,469 | $2.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 15,692 | 14,413 | $1.94M |
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 2,270 | 1,550 | $871K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.2% | 4,771 | 4,041 | $691K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.1% | 7,081 | 4,874 | $460K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.6% | 2,766 | 2,448 | $346K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.4% | 2,120 | 1,772 | $328K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.4% | 2,869 | 2,518 | $326K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.2% | 1,003 | 830 | $317K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.8% | 3,160 | 775 | $285K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 855 | 745 | $246K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 1,160 | 856 | $157K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.0% | 2,763 | 1,556 | $148K |
138 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 423 | $139K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 612 | $126K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.6% | 657 | $123K |
| 80053 | Comprehensive metabolic panel | <1% | 5,337 | $71K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 285 | $71K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 209 | $66K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 580 | $58K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 519 | $49K |
| G0378 | Hospital observation service, per hour | <1% | 522 | $39K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,254 | $32K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 146 | $31K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 407 | $31K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 632 | $29K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,009 | $25K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,188 | $24K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,362 | $23K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,671 | $23K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 83 | $21K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 842 | $21K |
| 82607 | <1% | 764 | $18K | |
| 80061 | Lipid panel | <1% | 1,257 | $18K |
| 84439 | <1% | 1,085 | $16K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,366 | $16K |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,679 | $16K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 437 | $14K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,095 | $14K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 148 | $14K |
| 73562 | <1% | 482 | $12K | |
| 97162 | <1% | 167 | $12K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 233 | $10K |
| 73630 | <1% | 466 | $10K | |
| 85027 | <1% | 1,014 | $10K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 74 | $9K |
| 83735 | <1% | 2,640 | $8K | |
| 73130 | <1% | 397 | $8K | |
| 96367 | <1% | 155 | $7K | |
| 82570 | <1% | 670 | $7K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 35 | $7K |
| 73610 | <1% | 393 | $7K | |
| 82728 | <1% | 412 | $7K | |
| 73030 | <1% | 242 | $7K | |
| 86140 | <1% | 452 | $6K | |
| 72100 | <1% | 162 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 816 | $5K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 52 | $5K |
| 74018 | <1% | 135 | $5K | |
| 83540 | <1% | 466 | $4K | |
| 83970 | <1% | 137 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,999 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,181 | $4K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,715 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 203 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 354 | $3K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 234 | $3K |
| 80076 | <1% | 955 | $3K | |
| 83550 | <1% | 388 | $3K | |
| 94729 | <1% | 38 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 137 | $3K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 121 | $3K |
| 81001 | <1% | 762 | $3K | |
| 83880 | <1% | 556 | $3K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $2K |
| 27096 | <1% | 45 | $2K | |
| 82043 | <1% | 321 | $2K | |
| 12001 | <1% | 13 | $2K | |
| 84484 | <1% | 2,260 | $2K | |
| 73110 | <1% | 93 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 203 | $2K |
| 85610 | <1% | 1,881 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 25 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 128 | $2K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 39 | $2K |
| 81003 | <1% | 3,191 | $2K | |
| 96376 | <1% | 987 | $1K | |
| 82746 | <1% | 119 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,484 | $1K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 22 | $1K |
| 85652 | <1% | 231 | $1K | |
| 85379 | <1% | 828 | $1K | |
| 97161 | <1% | 50 | $1K | |
| 83690 | <1% | 1,820 | $983.34 | |
| 84100 | <1% | 257 | $963.26 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 248 | $941.87 |
| 73502 | <1% | 49 | $911.11 | |
| 84550 | <1% | 170 | $853.21 | |
| 84156 | <1% | 159 | $832.29 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 27 | $640.13 |
| 80069 | <1% | 33 | $576.41 | |
| 99442 | <1% | 44 | $562.76 | |
| 90715 | <1% | 40 | $554.25 | |
| 82077 | <1% | 498 | $546.72 | |
| 85730 | <1% | 709 | $464.72 | |
| 87040 | <1% | 273 | $441.83 | |
| 81025 | <1% | 1,586 | $368.83 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 13 | $325.83 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,288 | $298.07 |
| 73080 | <1% | 14 | $294.79 | |
| 87077 | <1% | 196 | $258.18 | |
| 83605 | <1% | 906 | $199.33 | |
| 87186 | <1% | 45 | $168.54 | |
| 86803 | <1% | 13 | $155.77 | |
| 94664 | <1% | 220 | $102.65 | |
| 82803 | <1% | 114 | $99.74 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,261 | $94.93 |
| 73590 | <1% | 14 | $86.73 | |
| 80143 | <1% | 44 | $59.86 | |
| 82550 | <1% | 17 | $56.81 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 393 | $43.59 |
| 84145 | <1% | 63 | $33.94 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 315 | $25.58 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 916 | $20.63 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 446 | $19.62 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 150 | $18.56 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 77 | $17.05 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 212 | $11.47 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 780 | $9.20 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 59 | $8.76 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 108 | $8.40 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 71 | $2.82 |
| J2704 | Injection, propofol, 10 mg | <1% | 418 | $2.13 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 306 | $1.80 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 68 | $1.17 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 14 | $1.11 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 391 | $0.03 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 39 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 152 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 14 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 24 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 43 | $0.00 |
| A9270 | Non-covered item or service | 0% | 29 | $0.00 |
| 94760 | 0% | 12 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 61 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 14 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 12 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 22 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 29 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 28 | $0.00 |
| 80179 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHARP, KEVIN (SR VP)
Parent organizationPROMEDICA HEALTH SYSTEM
| Provider | Location | Paid |
|---|---|---|
| The Toledo Hospital | Toledo, OH | $151.22M |
| Emma L. Bixby Medical Center | Adrian, MI | $18.35M |
| Bay Park Community Hospital | Oregon, OH | $16.39M |
| Community Health Center of Branch County | Coldwater, MI | $11.80M |
| Defiance Hospital INC. | Defiance, OH | $11.55M |
| Memorial Hospital | Fremont, OH | $11.40M |
| Toledo Hospital | Toledo, OH | $2.38M |
| Herrick Memorial Hospital, INC. | Tecumseh, MI | $1.82M |
| Flower Hospital | Sylvania, OH | $368K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.